SIRT With Tremelimumab and Durvalumab for Resectable HCC
NCT: NCT05701488 · ACTIVE_NOT_RECRUITING
Brief Summary
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventions involved in this study are: * Durvalumab (a type of immunotherapy) * Tremelimumab (a type of immunotherapy) * Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere bead)
Frequently Asked Questions
What is SIRT With Tremelimumab and Durvalumab for Resectable HCC?
SIRT With Tremelimumab and Durvalumab for Resectable HCC is a clinical trial registered under NCT05701488. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT05701488?
The current status of NCT05701488 (SIRT With Tremelimumab and Durvalumab for Resectable HCC) is: ACTIVE_NOT_RECRUITING.
When did SIRT With Tremelimumab and Durvalumab for Resectable HCC start?
SIRT With Tremelimumab and Durvalumab for Resectable HCC started on 2023-04-21.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.